Kingsview Wealth Management LLC Cuts Stock Holdings in CVS Health Corporation $CVS

Kingsview Wealth Management LLC decreased its holdings in shares of CVS Health Corporation (NYSE:CVS) by 65.5% during the fourth quarter, HoldingsChannel reports. The firm owned 36,007 shares of the pharmacy operator’s stock after selling 68,425 shares during the period. Kingsview Wealth Management LLC’s holdings in CVS Health were worth $2,858,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in CVS. Fidelis Capital Partners LLC grew its position in shares of CVS Health by 11.4% in the 4th quarter. Fidelis Capital Partners LLC now owns 18,644 shares of the pharmacy operator’s stock worth $1,480,000 after buying an additional 1,913 shares during the last quarter. Knights of Columbus Asset Advisors LLC grew its position in shares of CVS Health by 19.7% in the 4th quarter. Knights of Columbus Asset Advisors LLC now owns 4,700 shares of the pharmacy operator’s stock worth $373,000 after buying an additional 773 shares during the last quarter. Flputnam Investment Management Co. grew its position in shares of CVS Health by 38.6% in the 4th quarter. Flputnam Investment Management Co. now owns 10,331 shares of the pharmacy operator’s stock worth $820,000 after buying an additional 2,876 shares during the last quarter. Poinciana Advisors Group LLC purchased a new position in shares of CVS Health in the 4th quarter worth approximately $202,000. Finally, Integrity Alliance LLC. grew its position in shares of CVS Health by 381.5% in the 4th quarter. Integrity Alliance LLC. now owns 27,198 shares of the pharmacy operator’s stock worth $2,158,000 after buying an additional 21,549 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Stock Down 2.2%

NYSE:CVS opened at $90.97 on Friday. The company has a market cap of $116.06 billion, a PE ratio of 40.07, a P/E/G ratio of 0.89 and a beta of 0.60. CVS Health Corporation has a twelve month low of $58.50 and a twelve month high of $98.43. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The company’s 50 day moving average is $82.07 and its two-hundred day moving average is $79.55.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.36. The company had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. CVS Health’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Analysts anticipate that CVS Health Corporation will post 7.44 EPS for the current year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 2.9%. The ex-dividend date was Thursday, April 23rd. CVS Health’s payout ratio is presently 117.18%.

Insider Activity at CVS Health

In other CVS Health news, Director Larry Robbins sold 370,462 shares of CVS Health stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the sale, the director directly owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. The trade was a 7.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 3,441,551 shares of company stock valued at $323,703,977. Company insiders own 0.85% of the company’s stock.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Caremark said it will restore coverage of Eli Lilly’s Zepbound and add Lilly’s new obesity pill to its standard drug plans, a move that could boost CVS’s pharmacy-benefit relevance and improve customer access to GLP-1 medications. CVS brings back coverage for Lilly’s obesity drug Zepbound
• Positive Sentiment: The company announced expanded GLP-1 coverage options, which management framed as improving affordability and access while supporting more sustainable long-term coverage. CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications with Expanded Coverage Options
• Positive Sentiment: CVS Health expanded its collaboration with Salesforce to streamline call center interactions using AI, which could improve service quality and operating efficiency across its member and provider base. CVS Health to Deliver Faster, More Personalized Call Center Care for Millions of Members with Salesforce’s Agentforce Health
• Positive Sentiment: CVS Health also launched Aetna Mental Health On Demand and continued building out digital health capabilities, reinforcing its integrated care strategy. CVS Health Expands Integrated Care With Virtual Mental Health AI And GLP 1
• Neutral Sentiment: CVS received a Newsweek AI Impact Award for prescription-interpretation technology, highlighting innovation in pharmacy workflow and medication safety. CVS Health recognized for technology that improves medication safety and patient care
• Neutral Sentiment: Glenview Capital said CVS remains one of its top holdings, which supports investor confidence but does not by itself change fundamentals. Glenview Capital Keeps CVS Health (CVS) Among Top Holdings

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Leerink Partners reaffirmed an “outperform” rating and issued a $98.00 price objective on shares of CVS Health in a research report on Thursday, March 5th. Barclays lifted their price objective on shares of CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 26th. Wolfe Research cut their price objective on shares of CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a research report on Monday, March 2nd. TD Cowen lifted their price objective on shares of CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Finally, Royal Bank Of Canada lifted their price objective on shares of CVS Health from $93.00 to $107.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. Twenty-two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, CVS Health presently has a consensus rating of “Moderate Buy” and an average target price of $98.88.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.